Mitoxantrone Completed Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00143975Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
NCT02686593Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
NCT00774046High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML